Metro Health – University of Michigan Health to Use Insulin Management Platform Glytec

Metro Health – University of Michigan Health in Wyoming, south of Grand Rapids, will use Massachusetts-based Glytec’s eGlycemic Management System to advance standardization of best practice. The software as a medical device platform is patented and FDA cleared.
1367
Metro Health – University of Michigan Health
Metro Health – University of Michigan Health has partnered with Glytec to better manage its insulin administration. // Photo courtesy of Metro Health – University of Michigan Health

Metro Health – University of Michigan Health in Wyoming, south of Grand Rapids, will use Massachusetts-based Glytec’s eGlycemic Management System to advance standardization of best practice. The software as a medical device platform is patented and FDA cleared.

“We’ve been using an intravenous insulin dosing tool in our critical care units for a number of years,” says Dr. Ronald Grifka, chief medical officer for Metro Health – University of Michigan Health. “Partnering with Glytec will allow us to support our patients and clinicians in a more comprehensive manner, with integrated solutions that address all areas of care, including subcutaneous basal-bolus insulin on the inpatient floors, where 90 percent of all insulin is administered.”

About 30 to 40 percent of patients require insulin therapy during hospitalization because they have diabetes or their blood sugar becomes elevated due to the stresses of surgery or other acute conditions. Glytec’s solution will offer evidence-based, technology-enabled decision support to ensure both intravenous and subcutaneous insulin therapy are managed safely and effectively according to standards established by the American Diabetes Association and the American Association of Clinical Endocrinologists.

The company also will provide a suite of professional services designed to help facilitate and support clinical practice change and ongoing quality improvement.

“With Glytec’s solution, we are positioning ourselves to achieve best practice for all patients,” says Grifka. “No matter what metro floor or unit they’re treated on, no matter which of our clinicians is caring for them, every patient will receive the same level of excellent care.

“We will deliver personalized insulin therapy that is responsive to a patient’s changing needs, and dose adjustments will be made in a very timely and precise manner. This includes transitions from intravenous to subcutaneous insulin therapy – when patients are transferred from critical care units to step-down or medical-surgical units – as well as transitions from hospital to home. These measures will help reduce both length of stay and readmissions, consistent with many published studies of the eGMS platform.”

Glytec modules provide hyperglycemia surveillance, glycemic status monitoring, robust analytics, reporting, and more.

Facebook Comments